Monash IVF Group Ltd (ASX: MVF) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Monash IVF Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $481.20 million
P/E Ratio 20.32
Dividend Yield 4.10%
Shares Outstanding 389.63 million
Earnings per share -0.017
Dividend per share 0.05
Year To Date Return -2.31%
Earnings Yield 4.92%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Monash IVF Group Ltd (ASX: MVF)
    Latest News

    a woman
    ⏸️ Investing

    Virtus Health Ltd share price climbs 4.7% on healthy report

    Virtus Health Ltd (ASX:VRT) reported solid growth in its result.

    Read more »

    a woman
    ⏸️ Investing

    These out-of-favour healthcare shares could rebound in 2018

    The healthcare sector has been a standout for investors in 2017 but there is a small group of laggards that…

    Read more »

    a woman
    ⏸️ Investing

    Is this the best healthcare stock?

    Is NIB Holdings Ltd (ASX:NHF) the best healthcare share on the ASX?

    Read more »

    a woman
    ⏸️ Investing

    M&A becoming a big theme for 2018: who are the next targets?

    The $33 billion buyout of Westfield Corp Ltd (ASX: WFD) is likely to pave the way for other mega deals…

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares are ending the week with a bang

    The GetSwift Ltd (ASX:GSW) share price is one of four ending the week with a bang. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    Monash IVF Group Ltd shares higher on insider buying

    The Monash IVF Group Ltd (ASX:MVF) share price has climbed higher on Friday following a spate of insider buying…

    Read more »

    a woman
    ⏸️ Investing

    Have the share prices of Virtus Health Ltd and Monash IVF Group Ltd found a bottom?

    It has not been a good year for IVF-related stocks but there's finally light at the end of the tunnel,…

    Read more »

    a woman
    ⏸️ Investing

    3 exciting small cap healthcare shares on my watchlist

    These 3 shares will hopefully create big returns.

    Read more »

    a woman
    ⏸️ Investing

    Why the Monash IVF Group Ltd share price was crushed today

    The Monash IVF Group Ltd (ASX:MVF) share price has been one of the worst performers on the market on Friday.…

    Read more »

    a woman
    ⏸️ Investing

    Are these beaten down ASX shares too cheap to ignore?

    Not all shares have been as lucky as a2 Milk Company Ltd (Australia) (ASX:A2M) this year. Are these beaten down…

    Read more »

    a woman
    ⏸️ Investing

    Are these beaten down healthcare shares in the bargain bin?

    The S&P/ASX 200 Health Care (Index:^AXHJ) (ASX:XHJ) may have gained 14% year-to-date, but not all healthcare shares have been so…

    Read more »

    a woman
    ⏸️ Investing

    Are these beaten down shares in the bargain bin?

    The Myer Holdings Ltd (ASX:MYR) share price is one of three that have been hammered recently. Are they in the…

    Read more »

    Frequently Asked Questions

    Yes, Monash IVF Group has historically paid two fully franked shareholder dividends a year.

    Monash IVF Group generally pays its shareholder dividends in April and October. 

    Monash IVF Group listed on the ASX on 26 June 2014.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    05 Sep 2024 $0.0250 100.00% Final 11 Oct 2024
    07 Mar 2024 $0.0250 100.00% Interim 05 Apr 2024
    07 Sep 2023 $0.0220 100.00% Final 11 Oct 2023
    08 Mar 2023 $0.0220 100.00% Interim 06 Apr 2023
    08 Sep 2022 $0.0220 100.00% Final 07 Oct 2022
    07 Mar 2022 $0.0220 100.00% Interim 04 Apr 2022
    09 Sep 2021 $0.0210 100.00% Final 08 Oct 2021
    09 Mar 2021 $0.0210 100.00% Interim 07 Apr 2021
    05 Mar 2020 $0.0210 100.00% Interim 02 Oct 2020
    05 Sep 2019 $0.0300 100.00% Final 11 Oct 2019
    06 Sep 2018 $0.0260 100.00% Final 12 Oct 2018
    08 Mar 2018 $0.0340 100.00% Interim 06 Apr 2018
    06 Sep 2017 $0.0000 100.00% Final 13 Oct 2017
    02 Mar 2017 $0.0430 100.00% Interim 07 Apr 2017
    06 Sep 2016 $0.0450 100.00% Final 14 Oct 2016
    08 Mar 2016 $0.0400 100.00% Interim 08 Apr 2016

    MVF ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Monash IVF Group Ltd

    Monash IVF Group Ltd (ASX: MVF) is a specialist assisted reproductive services provider. The company offers fertility treatments and specialist diagnostic obstetric and gynaecological ultrasound services. Monash is among the leading providers of assisted reproductive services in Australia and Malaysia. It also has a cooperative agreement with a hospital in China. 

    MVF Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Dec 2024 $1.24 $0.02 1.64% 485,936 $1.22 $1.24 $1.21
    19 Dec 2024 $1.22 $-0.02 -1.62% 321,736 $1.24 $1.24 $1.21
    18 Dec 2024 $1.24 $-0.01 -0.80% 333,209 $1.26 $1.26 $1.23
    17 Dec 2024 $1.25 $0.02 1.63% 272,207 $1.24 $1.26 $1.23
    16 Dec 2024 $1.23 $-0.02 -1.60% 911,094 $1.25 $1.26 $1.23
    13 Dec 2024 $1.25 $0.00 0.00% 609,225 $1.26 $1.26 $1.24
    12 Dec 2024 $1.25 $0.02 1.63% 294,782 $1.24 $1.26 $1.23
    11 Dec 2024 $1.23 $-0.03 -2.39% 1,024,415 $1.26 $1.26 $1.23
    10 Dec 2024 $1.26 $-0.01 -0.79% 613,454 $1.29 $1.29 $1.25
    09 Dec 2024 $1.26 $0.02 1.62% 849,712 $1.25 $1.28 $1.24
    06 Dec 2024 $1.24 $-0.01 -0.80% 248,872 $1.25 $1.26 $1.23
    05 Dec 2024 $1.25 $0.02 1.63% 389,962 $1.25 $1.25 $1.23
    04 Dec 2024 $1.23 $-0.01 -0.81% 978,202 $1.25 $1.25 $1.22
    03 Dec 2024 $1.24 $0.03 2.48% 548,464 $1.22 $1.25 $1.22
    02 Dec 2024 $1.21 $0.01 0.83% 311,446 $1.22 $1.22 $1.20
    29 Nov 2024 $1.20 $0.00 0.00% 348,238 $1.20 $1.21 $1.19
    28 Nov 2024 $1.20 $-0.02 -1.65% 439,881 $1.22 $1.25 $1.20
    27 Nov 2024 $1.22 $0.05 4.27% 883,774 $1.17 $1.23 $1.16
    26 Nov 2024 $1.17 $0.04 3.54% 776,549 $1.14 $1.17 $1.13
    25 Nov 2024 $1.13 $0.00 0.00% 353,718 $1.14 $1.14 $1.13
    22 Nov 2024 $1.13 $0.00 0.00% 205,456 $1.13 $1.13 $1.13

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    03 Dec 2024 Michael Knaap Issued 614,447 $761,914
    Issue of securities. 1,664,479 Rights
    31 Oct 2024 Josef Czyzewski Transfer 19,101 $22,443
    Off-market transfer. Assuming off market transfer of shares
    31 Oct 2024 Josef Czyzewski Transfer 19,101 $22,443
    Off-market transfer. Assuming off market transfer of shares
    16 Sep 2024 Catherine (Cathy) Aston Buy 2,000 $2,422
    On-market trade.
    16 Sep 2024 Catherine (Cathy) Aston Buy 75,000 $90,847
    On-market trade.
    13 Sep 2024 Michael Knaap Exercise 466,166 $550,075
    Conversion of securities. 1,050,032 Rights
    13 Sep 2024 Michael Knaap Buy 157,317 $185,634
    Conversion of securities.
    17 Apr 2024 Michael Knaap Exercise 501,629 $722,345
    Conversion of securities. 1,516,198 Rights
    17 Apr 2024 Michael Knaap Buy 577,325 $831,348
    Conversion of securities.
    17 Apr 2024 Michael Knaap Exercise 501,629 $722,345
    Conversion of securities. 1,516,198 Rights
    17 Apr 2024 Michael Knaap Issued 501,629 $722,345
    Conversion of securities.
    17 Apr 2024 Michael Knaap Issued 75,696 $109,002
    Dividend Reinvestment Plan (DRP).

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Zita Peach Non-Executive Director Oct 2016
    Ms Peach has more than 25 years of commercial experience in the pharmaceutical, biotechnology, medical devices and health services industries, and has worked for industry players such as CSL Limited, Fresenius Kabi and Merck Sharp & Dohme, the Australian subsidiary of Merck Inc. Zita is currently a Non-Executive Director of three private equity owned companies, Icon Group Pty Ltd, VetPartners Pty Ltd and Nucleus Network Pty Ltd. Zita is also the Chair of the Olivia Newton John Cancer Research Institute. Former directorships (last 3 years): Starpharma Holdings Limited.
    Mr Richard Hugh Davis Non-Executive ChairmanNon-Executive Director Jun 2014
    Mr. Davis worked for InvoCare for 20 years until 2008. For the majority of that time he held the position of CEO and managed the growth of that business through a number of ownership changes and over 20 acquisitions, including offshore in Singapore. Prior to InvoCare Limited, Richard worked as an accounting partner of Bird Cameron. He is member of risk committee.
    Mr Neil John Broekhuizen Non-Executive Director Jun 2014
    Mr. Broekhuizen is the Joint Chief Executive Officer of Ironbridge. Neil has over 30 years' experience in the finance industry including 28 years in private equity with Investcorp and Bridgepoint in Europe and Ironbridge in Australia. He has sat on the Ironbridge Investment Committee since inception. Former directorships (last 3 years): Bravura Solutions Limited. He is member of Risk Committee.
    Mr Michael Damian Knaap Chief Executive OfficerManaging Director Sep 2015
    Mr Knaap has 30 years of experience in executive positions with a financial, operational, strategic and leadership background in Healthcare and FMCG industries. Prior to joining MVF Group, Michael was with Patties Foods Limited where he held a number of executive positions over six years, including the role of Chief Financial Officer and Company Secretary.
    Dr Richard Charles Henshaw Executive Director Apr 2014
    Dr Henshaw MD FRANZCOG FRCOG has practiced in the field of reproductive medicine since 1995. Richard works as a Fertility Specialist for the Group. Richard has served on many national bodies, including RANZCOG Council, the IVF Medical Directors Group of Australia and New Zealand, and the Reproductive Technology Accreditation Committee.
    Ms Catherine Jane West Non-Executive Director Sep 2020
    Ms West has over 25 years of legal, business affairs and strategy experience in customer focused businesses in the media, entertainment, telecommunications and medical sectors in Australia, the United Kingdom and Europe. Catherine is Non Executive Director of Peter Warren Automotive Group. In addition, she is Chair of the National Institute of Dramatic Art (NIDA), a Director of the NIDA Foundation and Chair of the Board of Governors of Wenona School. Catherine was also until recently, a Director of the Sydney Breast Cancer Foundation Limited until her resignation on 30th June 2024. She formerly held directorship with Endeavour Group.
    Ms Catherine (Cathy) Ann Aston Non-Executive Director Feb 2024
    Ms. Catherine Aston is an experienced Non-Executive Director / Chair of listed and unlisted entities covering technology, financial services, marketing services, health and government sectors across Australia and Asia. Catherine has a commercial background with executive roles in finance, marketing and strategy, including as CFO for Telstra International and Chief Executive Officer of a mobiles joint venture in Sri Lanka. Catherine is currently a Non Executive Director of Macquarie Investment Management Ltd (Chair of the Audit, Risk and Compliance committee), IVE Group Ltd (Chair of the Audit and Risk Committee) and IMB Bank Ltd (Chair). Catherine's advisory roles have included work with the NSW State Government and serving as an advisory board member of Avanseus Pty Ltd, a Singapore based AI business. Former directorships (last 3 years): Virtus Health Ltd, Integrated Research Ltd, Over the Wire Ltd.
    Mr Malik Jainudeen Chief Financial OfficerCompany Secretary Apr 2019
    -
    Jan Lagerwij Asia Managing Director
    -
    Malik Jainudeen Chief Financial OfficerCompany Secretary
    -
    Tedd Fuell Chief Governance & Risk Officer
    -
    Thierry Panthier Chief Information Officer
    -
    Fiona Allen Chief Marketing Officer
    -
    Hamish Hamilton Chief Operating Officer
    -
    Peggy North Chief People & Culture Officer
    -
    Deirdre Zander Fox Chief Scientific Officer
    -
    Sloane Karlson General Manager Projects
    -
    Prof Luk Rombauts Group Medical Director
    -
    Sarah Bollom Regional Donor & Surrogacy Manager
    -
    Monique Teodoro Regional Manager Day Surgeries
    -
    Rebecca Redden Regional Manager for Ultrasound SA/NT and Genetics
    -
    Claire Ellem Regional Manager QLD
    -
    Nicolette Curtis Regional Manager VIC & NSW
    -
    Kate Robertson Regional Manager WA
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 82,222,688 21.10%
    Citicorp Nominees Pty Limited 67,647,801 17.36%
    J P Morgan Nominees Australia Pty Limited 64,131,568 16.46%
    Argo Investments Limited 20,292,940 5.21%
    Washington H Soul Pattison And Company Limited 18,675,000 4.79%
    Bnp Paribas Nominees Pty Ltd 9,120,255 2.34%
    Palm Beach Nominees Pty Ltd 7,813,727 2.01%
    Ubs Nominees Pty Ltd 6,645,317 1.71%
    HSBC Custody Nominees (Australia) Limited A/C 2 3,648,216 0.94%
    Neweconomy Com Au Nominees Pty Limited 3,473,430 0.89%
    National Nominees Limited 3,376,384 0.87%
    Pacific Custodians Pty Limted 2,579,603 0.66%
    Ippoliti Pty Ltd 2,245,945 0.58%
    Mr Prashant Nadkarni 2,011,336 0.52%
    Vollenhoven Investments Pty Ltd 1,461,484 0.38%
    Mclachlan Future Fund Pty Ltd 1,447,787 0.37%
    Ong Administration Pty Ltd 1,300,000 0.33%
    BNP Paribas Nominees Pty Ltd i 1,201,906 0.31%
    Dalyne Pty Ltd 1,172,933 0.30%
    Citicorp Nominees Pty Limited i 1,170,000 0.30%

    Profile

    since

    Note